Health
Study shows benefits of early anticlotting therapy in moderate COVID-19: International RAPID Trial could contribute to clinical practice – Science Daily
New research shows that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with…
COVID-19 is marked by heightened inflammation and abnormal clotting in the blood vessels, particularly in the lungs, and is believed to contribute to progression to severe disease and death. New trial results show that administering a full dose of a standard…
Continue Reading
-
Business15 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business11 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General21 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Noosa News11 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred